Eli Lilly and Company has significantly expanded its oncology portfolio with the definitive agreement to acquire Ajax Therapeutics, a clinical-stage…
Read More
Ray Therapeutics Secures $125 Million Series B Funding to Accelerate Vision Restoration Pipeline
Ray Therapeutics, a biopharmaceutical company at the forefront of developing novel gene therapies for vision restoration, has successfully closed a…
Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell Therapy
BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
AbbVie Secures Up to $745 Million in Pain Pipeline Deal with Chinese Biopharma Haisco
AbbVie, a global biopharmaceutical giant, has finalized a significant strategic collaboration with Haisco Pharmaceutical Group, a prominent Chinese biopharmaceutical company.…
Read More
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion, Bolstering Neuroscience Pipeline
Eli Lilly and Company announced a significant move to acquire Centessa Pharmaceuticals, a UK-based biopharmaceutical company specializing in neuroscience, in…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline
Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read MoreYOU MAY HAVE MISSED
